+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Thyroid Eye Disease Treatments Market by Treatment Type, Route of Administration, Type, Diagnosis, End-User, Distribution - Global Forecast to 2030- Product Image
Thyroid Eye Disease Treatments Market by Treatment Type, Route of Administration, Type, Diagnosis, End-User, Distribution - Global Forecast to 2030- Product Image
Sale

Thyroid Eye Disease Treatments Market by Treatment Type, Route of Administration, Type, Diagnosis, End-User, Distribution - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5012989
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Thyroid Eye Disease Treatments Market grew from USD 2.67 billion in 2024 to USD 2.83 billion in 2025. It is expected to continue growing at a CAGR of 5.94%, reaching USD 3.78 billion by 2030.

Unveiling the Challenges and Opportunities in Thyroid Eye Disease

Thyroid eye disease presents a complex interplay of autoimmune responses that affect orbital tissues, posing significant clinical challenges and unmet medical needs. This introduction frames the evolving treatment landscape, highlighting how recent scientific breakthroughs have transformed therapeutic approaches. Emerging therapies targeting the underlying immunopathology of orbital inflammation are redefining the standard of care, while advances in surgical techniques continue to optimize functional and aesthetic outcomes.

Stakeholders across pharmaceutical, biotechnology, and medical device sectors are increasingly focused on addressing patient heterogeneity, tailoring interventions based on disease severity, activity, and individual risk factors. The interplay between systemic thyroid management and localized orbital treatments underscores the importance of integrated care pathways. As the industry accelerates its research efforts, this report illuminates the strategic imperatives for market entrants, established players, and healthcare providers seeking to enhance patient quality of life and cost-effective treatment algorithms.

Groundbreaking Transformations Shaping the TED Treatment Landscape

Recent years have witnessed a seismic shift in how clinicians and developers approach treatment for thyroid eye disease. The advent of targeted biologics has ushered in a new era, moving beyond generalized immunosuppression toward precision modulation of specific inflammatory mediators. Simultaneously, improved imaging modalities enable earlier detection of orbital changes, facilitating timely intervention and reducing irreversible tissue damage.

Surgical innovation has also played a pivotal role; minimally invasive orbital decompression and refined strabismus correction techniques have shortened recovery times and enhanced visual rehabilitation. Moreover, the integration of pharmacologic and surgical modalities within multidisciplinary care centers is redefining patient journeys, ensuring seamless transitions between medical management and procedural interventions. This transformation underscores the imperative for companies to invest in comprehensive solution portfolios that bridge therapeutic classes and administration routes, capitalizing on an increasingly holistic treatment paradigm.

Evaluating the 2025 U.S. Tariff Ripple Effects on Treatment Supply Chains

The introduction of revised tariff schedules in 2025 has exerted material influence on cost structures for therapies and surgical devices destined for the United States. Levies on imported biologic agents and specialized surgical equipment have elevated landed costs, necessitating a reassessment of pricing strategies and contractual terms with suppliers. Manufacturers and distributors have initiated negotiations around cost-sharing arrangements, local manufacturing partnerships, and tariff mitigation programs to shield end-users from abrupt burden shifts.

These market adjustments have also created an impetus for innovation in supply chain design. Companies are exploring nearshoring opportunities to circumvent high-tariff jurisdictions, while logistics providers are leveraging free trade zone enactments to streamline customs clearance. Simultaneously, payers and hospital systems are scrutinizing total cost of care, prompting providers to demonstrate clinical and economic value through robust real-world evidence. As stakeholders adapt to this new fiscal landscape, agility in sourcing, production, and pricing will determine competitive advantage.

In-Depth Examination of Market Segmentation Dynamics

The market’s intricate segmentation reveals nuanced opportunities and competitive contours. Based on treatment type, the therapeutic domain bifurcates into medical and surgical pathways: the medical spectrum encompasses corticosteroids, immunosuppressants, monoclonal antibodies, thyroid hormone control agents, and tyrosine kinase inhibitors, while the surgical category spans eyelid procedures, orbital decompression interventions, and strabismus corrections. Each subcategory reflects distinct clinical protocols, investment needs, and reimbursement considerations.

Route of administration further delineates market reach, as intravenous infusions deliver rapid systemic immunomodulation, oral formulations offer patient convenience and ambulatory management, and topical therapies target localized symptom relief. Differentiation between Type I and Type II disease underscores the importance of phenotypic classification in treatment selection and trial design. Diagnostic modalities, including blood testing, imaging scans, orbital ultrasound, and radioactive iodine uptake examinations, form the backbone of disease staging and treatment monitoring.

End-user segmentation highlights the diverse channels through which therapies are delivered, encompassing tertiary care hospitals, community outpatient centers, and specialized ophthalmology clinics. Distribution pathways span hospital pharmacies, online dispensing platforms, and brick-and-mortar retail outlets, each with unique regulatory and logistical frameworks. Recognizing these segmentation layers enables companies to tailor product launches, channel strategies, and clinical support programs to distinct stakeholder ecosystems.

Regional Market Variations and Growth Drivers

Geographic analysis uncovers contrasting growth trajectories shaped by regulatory environments, healthcare infrastructure, and market maturity. In the Americas, robust investment in biologic development and established clinical guidelines fuel adoption of advanced immunotherapies. The prevalence of specialized orbital centers and integrated care networks supports seamless patient management, while payer frameworks incentivize evidence-based protocols.

In Europe, Middle East & Africa, diverse reimbursement models and regulatory pathways create a mosaic of access challenges and opportunities. Countries with centralized health technology assessments favor cost-effectiveness data, prompting companies to align clinical programs with health economic outcomes. Simultaneously, emerging markets in the Middle East and North Africa are experiencing rising awareness, increased diagnostic capabilities, and investment in centers of excellence, setting the stage for rapid uptake of novel therapies.

Within the Asia-Pacific region, growing thyroid disease incidence and expanding healthcare budgets are driving demand for both pharmacologic and procedural interventions. Rapid urbanization and expanded insurance coverage in key markets catalyze patient outreach programs, while local manufacturing initiatives aim to reduce dependency on imports. Strategic partnerships and technology transfers offer pathways to scalability in this dynamic environment.

Competitive Landscape: Leading Players and Strategic Moves

Leading pharmaceutical corporations and innovative biotech firms are forging strategic alliances to secure pipeline depth and expand geographical presence. Companies with established biologic portfolios are advancing next-generation monoclonal antibodies and small-molecule inhibitors through late-stage clinical trials, while device manufacturers refine orbital decompression instrumentation and surgical adjuncts.

Key players are differentiating through robust real-world data initiatives, leveraging patient registries and longitudinal outcomes studies to validate long-term efficacy and safety profiles. Strategic acquisitions and licensing agreements are unlocking new molecular targets and bolstering surgical device catalogs. Competitive intensity is further amplified by emerging entrants that harness platform technologies, such as gene editing and targeted cytokine blockade, to pioneer first-in-class modalities.

This convergence of therapeutic innovation, digital health integration, and value demonstration underscores the importance of a multi-dimensional competitive strategy. Market leaders are investing in integrated service offerings, combining diagnostic solutions, patient support programs, and telehealth platforms to enhance engagement and adherence across the treatment continuum.

Strategic Actions to Drive Success in the TED Market

To capitalize on evolving market dynamics, industry leaders must adopt a multi-pronged approach that balances innovation, collaboration, and operational excellence. It is essential to establish partnerships across research institutions and clinical consortia to accelerate development timelines and validate mechanistic hypotheses. Co-development agreements with surgical device experts can streamline the integration of pharmacologic and surgical solutions.

Equally important is the refinement of patient access programs and reimbursement support services. Tailored educational initiatives for payers and physician networks will facilitate evidence uptake and formulary inclusion. Companies should also explore alternative commercial models, including outcome-based contracts and subscription frameworks, to align pricing with demonstrated patient benefits.

Operational resilience will hinge on supply chain diversification and tariff optimization strategies. Investing in regional manufacturing hubs and flexible distribution channels will mitigate regulatory and geopolitical risks. Finally, harnessing advanced analytics and digital platforms to monitor real-world outcomes will strengthen value propositions and inform continuous product refinement.

Robust Methodological Framework Supporting Insights

This report's insights derive from a rigorous mixed-methods approach that synthesizes quantitative data, qualitative interviews, and secondary research. Primary research involved in-depth discussions with ophthalmic specialists, immunologists, health economists, and supply chain executives, ensuring a 360-degree understanding of clinical, regulatory, and commercial drivers.

Secondary research encompassed peer-reviewed journals, regulatory filings, clinical trial databases, and financial disclosures from leading organizations. Tariff analysis was conducted using official trade documentation and customs databases, while market segmentation frameworks were validated through cross-referencing with industry associations and regional registries.

Analytical methodologies included comparative benchmarking, scenario analysis for tariff impact, and regional growth modeling. Data triangulation and iterative validation workshops with subject-matter experts ensured robustness and minimized bias. The result is an evidence-based narrative that supports informed strategic decision-making across the treatment continuum.

Synthesis of Key Findings and Forward-Looking Perspectives

This executive summary has outlined the multifaceted landscape of thyroid eye disease treatment, from pioneering immunotherapies to refined surgical techniques and the evolving implications of U.S. tariff policy. Deep segmentation analysis elucidates how therapeutic classes, administration routes, patient phenotypes, diagnostic tools, end-user channels, and distribution networks converge to shape commercial strategies.

Regional insights reveal differentiated pathways to growth, with each zone presenting unique regulatory and infrastructure considerations. The competitive audit underscores the imperative for integrated offerings that marry clinical innovation with real-world value demonstration. Actionable recommendations emphasize the importance of partnerships, flexible pricing models, and supply chain resilience.

As stakeholders navigate this complex environment, the alignment of scientific innovation with stakeholder needs and economic realities will define success. The strategic imperatives laid out herein serve as a roadmap for organizations seeking to deliver transformative treatments that improve patient outcomes while capturing sustainable market share.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Medical Treatment
      • Corticosteroids
      • Immunosuppressants
      • Monoclonal Antibodies
      • Thyroid Hormone Control
      • Tyrosine Kinase Inhibitors
    • Surgical Treatment
      • Eyelid Surgery
      • Orbital Decompression Surgery
      • Strabismus Surgery
  • Route of Administration
    • Intravenous
    • Oral
    • Topical
  • Type
    • Type I TED
    • Type II TED
  • Diagnosis
    • Blood Test
    • Imaging Test
    • Orbital Ultrasound
    • Radioactive Iodine Uptake Test
  • End-User
    • Hospitals
    • Outpatient Centers
    • Specialty Clinics
  • Distribution
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
      • Massachusetts
      • New Jersey
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Abbott Laboratories
  • AbbVie Inc.
  • ACELYRIN, INC.
  • Amgen Inc.
  • argenx SE
  • Bausch & Lomb Incorporated
  • Biocon Limited
  • BioXpress Therapeutics SA
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Genmab A/S
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Hetero Drugs Limited
  • Immunovant, Inc.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson Services Inc.
  • Lupin Limited
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sling Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viridian Therapeutics, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Thyroid Eye Disease Treatments Market, by Treatment Type
8.1. Introduction
8.2. Medical Treatment
8.2.1. Corticosteroids
8.2.2. Immunosuppressants
8.2.3. Monoclonal Antibodies
8.2.4. Thyroid Hormone Control
8.2.5. Tyrosine Kinase Inhibitors
8.3. Surgical Treatment
8.3.1. Eyelid Surgery
8.3.2. Orbital Decompression Surgery
8.3.3. Strabismus Surgery
9. Thyroid Eye Disease Treatments Market, by Route of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Topical
10. Thyroid Eye Disease Treatments Market, by Type
10.1. Introduction
10.2. Type I TED
10.3. Type II TED
11. Thyroid Eye Disease Treatments Market, by Diagnosis
11.1. Introduction
11.2. Blood Test
11.3. Imaging Test
11.4. Orbital Ultrasound
11.5. Radioactive Iodine Uptake Test
12. Thyroid Eye Disease Treatments Market, by End-User
12.1. Introduction
12.2. Hospitals
12.3. Outpatient Centers
12.4. Specialty Clinics
13. Thyroid Eye Disease Treatments Market, by Distribution
13.1. Introduction
13.2. Hospital Pharmacy
13.3. Online Pharmacy
13.4. Retail Pharmacy
14. Americas Thyroid Eye Disease Treatments Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Thyroid Eye Disease Treatments Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Thyroid Eye Disease Treatments Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Abbott Laboratories
17.3.2. AbbVie Inc.
17.3.3. ACELYRIN, INC.
17.3.4. Amgen Inc.
17.3.5. argenx SE
17.3.6. Bausch & Lomb Incorporated
17.3.7. Biocon Limited
17.3.8. BioXpress Therapeutics SA
17.3.9. Cipla Limited
17.3.10. Dr. Reddy’s Laboratories Ltd.
17.3.11. Eli Lilly and Company
17.3.12. F. Hoffmann-La Roche AG
17.3.13. Genmab A/S
17.3.14. GlaxoSmithKline PLC
17.3.15. H. Lundbeck A/S
17.3.16. Hetero Drugs Limited
17.3.17. Immunovant, Inc.
17.3.18. Intas Pharmaceuticals Ltd.
17.3.19. Johnson & Johnson Services Inc.
17.3.20. Lupin Limited
17.3.21. Merck KGaA
17.3.22. Novartis AG
17.3.23. Pfizer, Inc.
17.3.24. Regeneron Pharmaceuticals, Inc.
17.3.25. Sling Therapeutics, Inc.
17.3.26. Teva Pharmaceutical Industries Ltd.
17.3.27. Viridian Therapeutics, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. THYROID EYE DISEASE TREATMENTS MARKET MULTI-CURRENCY
FIGURE 2. THYROID EYE DISEASE TREATMENTS MARKET MULTI-LANGUAGE
FIGURE 3. THYROID EYE DISEASE TREATMENTS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. THYROID EYE DISEASE TREATMENTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. THYROID EYE DISEASE TREATMENTS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. THYROID EYE DISEASE TREATMENTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY THYROID HORMONE CONTROL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY EYELID SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORBITAL DECOMPRESSION SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STRABISMUS SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE I TED, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE II TED, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY IMAGING TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORBITAL ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY OUTPATIENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 64. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 65. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 66. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 67. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 69. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 70. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 72. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 73. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 74. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 75. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 77. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 90. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 92. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 98. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 99. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 100. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 101. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 103. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 104. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 106. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 108. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 109. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 112. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 113. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 114. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 115. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 116. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 117. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 120. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 122. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 123. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 124. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 125. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 127. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 128. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 129. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 130. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 131. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 132. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 133. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 135. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 136. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 137. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 138. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 140. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 141. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 143. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 144. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 146. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 147. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 148. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 149. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 151. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 152. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 153. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 154. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 155. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 156. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 157. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 159. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 160. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 161. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 162. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 163. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 164. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 165. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 167. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 168. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 169. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 170. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 171. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 172. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 173. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 175. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 176. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 177. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 178. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 179. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 180. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 181. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 183. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 184. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 185. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 186. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 187. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 188. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 189. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 191. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 192. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 193. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 203. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 204. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 205. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 206. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 208. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 209. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 210. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 211. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 212. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 213. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 214. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 216. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 217. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 218. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 219. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 220. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 221. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 222. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 224. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 225. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 226. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 227. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 228. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 229. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 230. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 232. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 233. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 234. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 235. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 236. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 237. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 238. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 240. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 241. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 242. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 243. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 246. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 248. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 249. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 250. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 251. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 252. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 253. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 254. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 256. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 257. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 258. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 272. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 273. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 274. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 275. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 276. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 277. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 278. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 279. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 280. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 281. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 282. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 283. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 284. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 285. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 286. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 287. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 288. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 289. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 290. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 291. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 292. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 293. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 294. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 295. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 296. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 297. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 298. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 299. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 300. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 301. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 302. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 303. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 304. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 305. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 306. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 308. SAUDI ARABIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)

Companies Mentioned

The companies profiled in this Thyroid Eye Disease Treatments market report include:
  • Abbott Laboratories
  • AbbVie Inc.
  • ACELYRIN, INC.
  • Amgen Inc.
  • argenx SE
  • Bausch & Lomb Incorporated
  • Biocon Limited
  • BioXpress Therapeutics SA
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Genmab A/S
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Hetero Drugs Limited
  • Immunovant, Inc.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson Services Inc.
  • Lupin Limited
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sling Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viridian Therapeutics, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages198
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.83 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.78 Billion
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Global Thyroid Eye Disease Treatment Market (2025 Edition): Analysis By Therapeutic Type (Monoclonal Antibodies, Corticosteroids, Vitamins, and Other Therapies), Route of Administration, Distribution Channel: Market Insights and Forecast (2021-2031) - Product Image

Global Thyroid Eye Disease Treatment Market (2025 Edition): Analysis By Therapeutic Type (Monoclonal Antibodies, Corticosteroids, Vitamins, and Other Therapies), Route of Administration, Distribution Channel: Market Insights and Forecast (2021-2031)

  • Report
  • 238 Pages
  • Global
From
Thyroid Eye Disease (TED) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Thyroid Eye Disease (TED) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Thyroid Eye Disease (TED) Global Market Report 2025 - Product Image

Thyroid Eye Disease (TED) Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Graves' Ophthalmopathy - Pipeline Insight, 2025 - Product Image

Graves' Ophthalmopathy - Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From
Diabetic Eye Disease Devices Market by Technology, Device Type, End User, Application, Distribution Channel - Global Forecast to 2030 - Product Image

Diabetic Eye Disease Devices Market by Technology, Device Type, End User, Application, Distribution Channel - Global Forecast to 2030

  • Report
  • 184 Pages
  • Global
From

About the Thyroid Eye Disease Treatment Market

Thyroid Eye Disease (TED) is a rare autoimmune disorder that affects the eyes and surrounding tissues. It is caused by an overactive thyroid gland, which produces antibodies that attack the muscles and fatty tissues around the eyes. Symptoms of TED include bulging eyes, double vision, and dry eyes. Treatment for TED typically involves a combination of medications, surgery, and lifestyle changes. Medications used to treat TED include corticosteroids, immunosuppressants, and antithyroid drugs. Surgery may be used to correct double vision, reduce the bulging of the eyes, and improve the appearance of the eyes. Lifestyle changes such as avoiding smoking, reducing stress, and eating a healthy diet can also help manage the symptoms of TED. Companies in the Thyroid Eye Disease Treatment market include Allergan, Novartis, Pfizer, and Regeneron. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.